Eosinophilic Fasciitis Failing to Taper: Choosing the Steroid-Sparing Agent
A single patient whose eosinophilic fasciitis won't come off high-dose prednisone. The disagreement is between the best-studied steroid-sparing agent and the one that better fits his actual life.
Jerome P., 49, has worked as a landscaper for two decades, and traces the start of his illness to an unusually grueling week of manual work five months ago — the kind of strenuous exertion that, oddly, shows up again and again as a preceding trigger in eosinophilic fasciitis case series. Within days his forearms and lower legs developed painful, woody induration, and an exam finding called the groove sign — a visible depression along the path of a vein where the surrounding tissue has hardened around it — along with peripheral eosinophilia on his initial labs, confirmed the diagnosis. High-dose prednisone brought real early improvement.
Five months later, he can't taper below 20 milligrams a day without the skin tightening flaring again, and new contractures have developed at both wrists and ankles, limiting exactly the physical work his job requires. Twenty milligrams of daily prednisone for this long is also starting to show: new glucose intolerance on recent labs and early cushingoid features, in an otherwise-active 49-year-old who cannot sustain this dose indefinitely. Everything known about steroid-sparing options in eosinophilic fasciitis comes from retrospective cohorts rather than randomized trials. The largest of them, Wright and colleagues' 63-patient series drawn from three tertiary centers, found that corticosteroids combined with methotrexate produced the best outcomes of any regimen used; Lebeaux's earlier 34-patient French series pointed the same way. That is real evidence, and it is also the ceiling of what exists. Set against it is a fact the cohorts never had to weigh: he has five months of fibrosis already converting into fixed contractures at the wrists and ankles, which is to say the window in which any of this is a purely inflammatory problem is closing on him specifically — and a drug he cannot take reliably while swinging a mattock for a living is not the best-evidenced drug for him, whatever the charts say.
In clinic, new contractures on a prednisone dose he can't come down from
Methotrexate has the largest retrospective evidence base of any steroid-sparing option specifically in eosinophilic fasciitis. Wright's 63-patient series across three centers found corticosteroids plus methotrexate gave the best outcomes of any combination used, and Lebeaux's 34-patient series before it reported the same direction for exactly this failure-to-taper pattern. I'd start it.
I'm not disputing that methotrexate has the most cases behind it. But he's developed new glucose intolerance, and he does physically demanding manual labor for a living — methotrexate's own side-effect profile, fatigue and GI upset especially, plus the monitoring it requires, could be a genuinely poor fit for his day-to-day life.
Mycophenolate is a comparably reasonable steroid-sparing choice with a cleaner tolerability profile, even if its evidence specifically in this disease is thinner. "Most-studied" isn't the same as "best-suited to this particular patient's actual constraints."
I'd step outside the methotrexate-versus-mycophenolate question for a moment. Regardless of which one is chosen, his new wrist and ankle contractures are the more time-sensitive problem — EF fibrosis can become mechanically fixed rather than purely inflammatory within a matter of months.
Structured physical therapy and stretching need to start immediately, in parallel with whatever drug decision is made. Delaying that while the group settles on a steroid-sparing agent risks a joint problem that no drug, however well chosen, will later reverse.
Agreed: add methotrexate, begin structured physical therapy and stretching immediately for the wrist and ankle contractures, attempt a slower prednisone taper now that a steroid-sparing agent is in place, and monitor glucose given the emerging intolerance.
Not agreed: the dermatologist still believes mycophenolate would have been the better first choice given his job and metabolic trend, agreeing to methotrexate only with an explicit plan to switch early if tolerability becomes a real problem rather than waiting out a full trial.